Instructions for use, contraindications, composition of Plavix

Plavix prevents formation of blood clots and is prescribed to reduce the risk of circulation problems, stroke and heart attack.


antiplatelet agent

The nosological classification (ICD-10)

I20.0 Unstable angina

I21 Acute myocardial infarction

I24.9 Acute ischemic heart disease, unspecified

I25.2 Transferred last myocardial infarction

I48 Atrial fibrillation and flutter

I49.8 Other specified cardiac arrhythmias

I63 Cerebral infarction

I64 Stroke, not specified as hemorrhage or infarction

I73.9 Peripheral vascular disease, unspecified

I74 Embolism and thrombosis of arteries

Narrowing of the arteries I77.1

Z100 * CLASS XXII Surgical practice

Plavix - antiaggregant. Is a prodrug and an active metabolite which is an inhibitor of platelet aggregation.

Plavix – antiaggregant. Is a prodrug and an active metabolite which is an inhibitor of platelet aggregation.

Tablets, film-coated.

Active substance:

clopidogrel hydrogen sulfate in the form of II – 97,875 mg

(In terms of clopidogrel – 75 mg)

Excipients: mannitol – 68.925 mg; Macrogol 6000 – 34 mg; MCC (low water – 90 mm) – 31 mg; giproloza low substituted – 12.9 mg; hydrogenated castor oil – 3.3 mg

The casing film: Opadry pink (lactose monohydrate, hypromellose, titanium dioxide (E171), triacetin, iron oxide red dye (E172) – 7,5 mg carnauba wax – traces

Indications for use

Prevention of atherothrombotic complications:

adult patients with myocardial infarction (with a prescription from a few days to 35 days), ischemic stroke (with lapse of 7 days to 6 months) or diagnosed with peripheral arterial occlusive disease;

adult patients with acute coronary syndrome:

– Segment elevation ST (unstable angina or myocardial infarction without the Q wave), including patients who underwent stenting during percutaneous coronary intervention (in combination with ASA);

– C-segment elevation ST (acute myocardial infarction) for medical treatment and the possibility of thrombolysis (in combination with ASA).

– Prevention of atherothrombotic and thromboembolic events, including stroke, atrial fibrillation (atrial fibrillation).

– Patients with atrial fibrillation (atrial fibrillation), which have at least one risk factor for vascular events, are not eligible indirect anticoagulants and have a low risk of bleeding (in combination with ASA).


Hypersensitivity to clopidogrel or any of the excipients of the formulation;

severe hepatic impairment;

acute bleeding, such as bleeding peptic ulcer or intracranial hemorrhage;

rare hereditary galactose intolerance, lactase deficiency and glucose-galactose malabsorption;

pregnancy and lactation (see “Pregnancy and breastfeeding”.);

Children up to age 18 years (safety and efficacy not established).

With caution in the following conditions: moderate hepatic impairment, where possible predisposition to bleeding (limited clinical experience); renal insufficiency (limited clinical experience); trauma, surgical intervention (see “Special Instructions”.); in diseases in which there is a predisposition to bleeding (especially gastrointestinal or intraocular), especially while the use of drugs, which can cause damage to the gastrointestinal mucosa (such as ASA), and NAIP); in patients who have an increased risk of bleeding: due to trauma, surgery or other pathological conditions and in patients treated with ASA, heparin, warfarin, inhibitors of glycoprotein IIb / IIIa, NSAIDs, including selective COX-2 inhibitors, or SSRIs (see “Special Instructions”.); in patients with low activity of isoenzyme CYP2C19 (see “Pharmacokinetics” sub “Pharmacogenetics”, “Dosage and administration”, “Special Instructions”.); When specifying a history of allergic and hematological reactions to other thienopyridines (such as ticlopidine, prasugrel) (possibility of cross-allergic and hematological reactions, see “Special Instructions”.); at the recently adjourned transient ischemic attack or ischemic stroke.